Carmell Therapeutics Correlations
| CTCX Stock | 0.53 0.01 0.94% |
The current 90-days correlation between Carmell Therapeutics and Royalty Management Holding is 0.19 (i.e., Average diversification). The correlation of Carmell Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
Carmell Therapeutics Correlation With Market
Good diversification
The correlation between Carmell Therapeutics and DJI is -0.06 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Carmell Therapeutics and DJI in the same portfolio, assuming nothing else is changed.
Carmell |
Moving together with Carmell Stock
Moving against Carmell Stock
| 0.62 | VERA | Vera Therapeutics | PairCorr |
| 0.44 | DSGN | Design Therapeutics | PairCorr |
| 0.32 | VNDA | Vanda Pharmaceuticals | PairCorr |
| 0.58 | ELUT | Elutia Inc | PairCorr |
| 0.53 | VTRS | Viatris | PairCorr |
| 0.39 | VTVT | vTv Therapeutics | PairCorr |
| 0.35 | ELDN | Eledon Pharmaceuticals | PairCorr |
Related Correlations Analysis
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Carmell Stock performing well and Carmell Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Carmell Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| DEI | 1.69 | (0.03) | 0.00 | (0.02) | 0.00 | 2.77 | 11.24 | |||
| RMCO | 3.64 | 0.29 | 0.07 | (1.31) | 3.68 | 8.49 | 21.04 | |||
| GAINN | 0.23 | 0.01 | (0.01) | 0.55 | 0.23 | 0.54 | 1.77 | |||
| KRC | 1.69 | 0.00 | 0.00 | 0.02 | 2.52 | 3.37 | 12.11 | |||
| GRMHF | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| SEIC | 0.97 | 0.25 | 0.15 | 0.84 | 1.22 | 1.63 | 10.38 | |||
| STEP | 1.79 | 0.05 | 0.02 | 0.10 | 2.39 | 3.05 | 18.64 | |||
| TPG | 1.84 | 0.18 | 0.07 | 1.00 | 2.17 | 4.12 | 16.27 |
Carmell Therapeutics Corporate Executives
Elected by the shareholders, the Carmell Therapeutics' board of directors comprises two types of representatives: Carmell Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Carmell. The board's role is to monitor Carmell Therapeutics' management team and ensure that shareholders' interests are well served. Carmell Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Carmell Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.